Wall Street Zen Downgrades Context Therapeutics (NASDAQ:CNTX) to Strong Sell

Context Therapeutics (NASDAQ:CNTX) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Monday.

CNTX has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Maxim Group reduced their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Piper Sandler upped their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Guggenheim reaffirmed a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. Finally, D. Boral Capital reiterated a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $6.17.

Context Therapeutics Stock Performance

Shares of CNTX opened at $0.60 on Monday. Context Therapeutics has a 1 year low of $0.55 and a 1 year high of $3.62. The stock has a market cap of $55.13 million, a P/E ratio of -1.43 and a beta of 1.75. The stock’s 50-day moving average price is $1.42 and its two-hundred day moving average price is $2.01.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. As a group, equities analysts forecast that Context Therapeutics will post -0.39 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd lifted its position in Context Therapeutics by 858.8% in the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after acquiring an additional 91,008 shares in the last quarter. Quadrature Capital Ltd bought a new position in Context Therapeutics during the 4th quarter worth about $68,000. Marshall Wace LLP raised its stake in shares of Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the period. State Street Corp raised its stake in shares of Context Therapeutics by 8.5% in the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after purchasing an additional 13,000 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after buying an additional 188,202 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.